bumetanide has been researched along with Infant, Newborn, Diseases in 8 studies
Infant, Newborn, Diseases: Diseases of newborn infants present at birth (congenital) or developing within the first month of birth. It does not include hereditary diseases not manifesting at birth or within the first 30 days of life nor does it include inborn errors of metabolism. Both HEREDITARY DISEASES and METABOLISM, INBORN ERRORS are available as general concepts.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A recent Phase II randomized, controlled trial of bumetanide as an adjunctive treatment for neonatal seizures showed a robust efficacy signal and no evidence of toxicity." | 9.51 | Clarifications regarding bumetanide for neonatal seizures. ( Staley, KJ, 2022) |
| "Bumetanide, an inhibitor of the sodium-potassium-chloride cotransporter-1, has been suggested as an adjunct to phenobarbital for treating neonatal seizures." | 9.41 | Effects of bumetanide on neonatal seizures: A systematic review of animal and human studies. ( Athikarisamy, S; Farhat, A; Ghosh, S; Nagarajan, L; Rakshasbhuvankar, A; Rao, S, 2023) |
| "In his editorial, Kevin Staley criticizes our recent work demonstrating the lack of effect of bumetanide in a novel model of neonatal seizures." | 8.12 | Bumetanide for neonatal seizures: No light in the pharmacokinetic/dynamic tunnel. ( Kaila, K; Löscher, W, 2022) |
| "A recent Phase II randomized, controlled trial of bumetanide as an adjunctive treatment for neonatal seizures showed a robust efficacy signal and no evidence of toxicity." | 5.51 | Clarifications regarding bumetanide for neonatal seizures. ( Staley, KJ, 2022) |
| "Bumetanide, an inhibitor of the sodium-potassium-chloride cotransporter-1, has been suggested as an adjunct to phenobarbital for treating neonatal seizures." | 5.41 | Effects of bumetanide on neonatal seizures: A systematic review of animal and human studies. ( Athikarisamy, S; Farhat, A; Ghosh, S; Nagarajan, L; Rakshasbhuvankar, A; Rao, S, 2023) |
| "In his editorial, Kevin Staley criticizes our recent work demonstrating the lack of effect of bumetanide in a novel model of neonatal seizures." | 4.12 | Bumetanide for neonatal seizures: No light in the pharmacokinetic/dynamic tunnel. ( Kaila, K; Löscher, W, 2022) |
| "Neonatal stroke is the second cause of acute symptomatic neonatal seizures after hypoxic-ischemic encephalopathy." | 2.82 | Efficacy of the anti-seizure medications in acute symptomatic neonatal seizures caused by stroke. A systematic review. ( Criscione, R; Falsaperla, R; Marino, S; Pisani, F; Praticò, A; Ruggieri, M; Sortino, V, 2022) |
| " Half-life and mean residence time decreased markedly in the first month of life (p < 0." | 2.68 | Analysis of the variability in the pharmacokinetics and pharmacodynamics of bumetanide in critically ill infants. ( Blumer, JL; Myers, CM; Sullivan, JE; Witte, MK; Yamashita, TS, 1996) |
| " Data were evaluated by standard noncompartmental pharmacokinetic techniques." | 2.68 | Pharmacokinetics of bumetanide in critically ill infants. ( Blumer, JL; Myers, CM; Sullivan, JE; Witte, MK; Yamashita, TS, 1996) |
| "Seizures are a common manifestation of acute neurologic insults in neonates and are often resistant to the standard antiepileptic drugs that are efficacious in children and adults." | 2.50 | Pharmacotherapeutic targeting of cation-chloride cotransporters in neonatal seizures. ( Kahle, KT; Kaila, K; Puskarjov, M; Ruusuvuori, E, 2014) |
| "Bumetanide was highly bound to plasma proteins (approximately 97%) in all three populations studied." | 1.28 | Protein binding characteristics of bumetanide. ( Berry, NS; Edwards, DJ; Walker, PC, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (12.50) | 18.7374 |
| 1990's | 2 (25.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 4 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Staley, KJ | 1 |
| Kaila, K | 2 |
| Löscher, W | 1 |
| Sortino, V | 1 |
| Praticò, A | 1 |
| Marino, S | 1 |
| Criscione, R | 1 |
| Ruggieri, M | 1 |
| Pisani, F | 1 |
| Falsaperla, R | 1 |
| Rao, S | 1 |
| Farhat, A | 1 |
| Rakshasbhuvankar, A | 1 |
| Athikarisamy, S | 1 |
| Ghosh, S | 1 |
| Nagarajan, L | 1 |
| Puskarjov, M | 1 |
| Kahle, KT | 1 |
| Ruusuvuori, E | 1 |
| Sullivan, JE | 2 |
| Witte, MK | 2 |
| Yamashita, TS | 2 |
| Myers, CM | 2 |
| Blumer, JL | 2 |
| Walker, PC | 1 |
| Berry, NS | 1 |
| Edwards, DJ | 1 |
3 reviews available for bumetanide and Infant, Newborn, Diseases
| Article | Year |
|---|---|
Efficacy of the anti-seizure medications in acute symptomatic neonatal seizures caused by stroke. A systematic review.
Topics: Anticonvulsants; Bumetanide; Epilepsy; Humans; Infant, Newborn; Infant, Newborn, Diseases; Levetirac | 2022 |
Effects of bumetanide on neonatal seizures: A systematic review of animal and human studies.
Topics: Aminoglycosides; Animals; Anticonvulsants; Bumetanide; Epilepsy; Hearing Loss; Humans; Infant; Infan | 2023 |
Pharmacotherapeutic targeting of cation-chloride cotransporters in neonatal seizures.
Topics: Anticonvulsants; Brain; Bumetanide; Humans; Infant, Newborn; Infant, Newborn, Diseases; K Cl- Cotran | 2014 |
3 trials available for bumetanide and Infant, Newborn, Diseases
| Article | Year |
|---|---|
Clarifications regarding bumetanide for neonatal seizures.
Topics: Bumetanide; Epilepsy; Humans; Infant, Newborn; Infant, Newborn, Diseases; Seizures; Sodium Potassium | 2022 |
Analysis of the variability in the pharmacokinetics and pharmacodynamics of bumetanide in critically ill infants.
Topics: Aging; Bumetanide; Critical Illness; Diuretics; Female; Heart Diseases; Humans; Infant; Infant, Newb | 1996 |
Pharmacokinetics of bumetanide in critically ill infants.
Topics: Area Under Curve; Bumetanide; Chromatography, High Pressure Liquid; Critical Illness; Diuretics; Fem | 1996 |
2 other studies available for bumetanide and Infant, Newborn, Diseases
| Article | Year |
|---|---|
Bumetanide for neonatal seizures: No light in the pharmacokinetic/dynamic tunnel.
Topics: Bumetanide; Epilepsy; Humans; Infant, Newborn; Infant, Newborn, Diseases; Seizures; Sodium Potassium | 2022 |
Protein binding characteristics of bumetanide.
Topics: Adult; Age Factors; Bilirubin; Blood Proteins; Bumetanide; Diuretics; Fetal Blood; Humans; Infant, N | 1989 |